ACA
JAZZ icon

Aptus Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Aptus Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9,409
Closed -$1.21M – 532
2019
Q3 		$1.21M Sell
9,409
-2,266
-19% -$304K 0.07% 178
2019
Q2 		$1.66M Sell
11,675
-1,295
-10% -$174K 0.23% 69
2019
Q1 		$1.85M Buy
12,970
+2,368
+22% +$309K 0.32% 68
2018
Q4 		$1.31M Buy
+10,602
New +$1.57M 0.35% 54

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Aptus Capital Advisors's JAZZ Position: Q4 2019 in Review

Aptus Capital Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2019, closing a stake of 9,409 shares — an estimated $1.21M sold.

Aptus Capital Advisors first reported a position in JAZZ in Q4 2018 and held it in 4 quarters. The position peaked at $1.85M in Q1 2019. 446 funds tracked by Wall St. Rank hold JAZZ as of Q4 2019.

  • Aptus Capital Advisors reported no remaining Jazz Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Aptus Capital Advisors sold 9,409 Jazz Pharmaceuticals shares in Q4 2019, an estimated $1.21M.
  • Aptus Capital Advisors first reported a position in Jazz Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Aptus Capital Advisors's Jazz Pharmaceuticals position peaked at $1.85M in Q1 2019.
  • 446 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2019.

Based on Aptus Capital Advisors's 13F filing for Q4 2019, filed 10 Feb 2020.